{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T11:20:20Z","timestamp":1788002420169,"version":"build-2784847793"},"reference-count":22,"publisher":"SAGE Publications","issue":"5","license":[{"start":{"date-parts":[[2017,7,1]],"date-time":"2017-07-01T00:00:00Z","timestamp":1498867200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"DOI":"10.13039\/100007013","name":"F. Hoffmann-La Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007013","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Toxicol Pathol"],"published-print":{"date-parts":[[2017,7]]},"abstract":"<jats:p>Obinutuzumab (GA101, Gazyva\u2122, Gazyvaro\u00ae, F. Hoffmann-La Roche AG, Basel, Switzerland) is a humanized, glycoengineered type II antibody targeted against CD20. The preclinical safety evaluation required to support clinical development and marketing authorization of obinutuzumab included repeat-dose toxicity studies in cynomolgus monkeys for up to 6-month dosing with a 9-month recovery period. Results from those studies showed decreases in circulating B cells and corresponding B-cell depletion in lymphoid tissues, consistent with the desired pharmacology of obinutuzumab. Hypersensitivity reactions were noted at all doses in the 6-month study and were attributed to the foreign recognition of the drug construct in cynomolgus monkeys. Findings in monkeys were classified as acute hypersensitivity reactions that were evident immediately after dosing, such as excessive salivation, erythema, pruritus, irregular respiration, or ataxia, or chronic hypersensitivity reactions characterized by glomerulonephritis, arteritis\/periarteritis, and inflammation in several tissues including serosal\/adventitial inflammation. Immune complex deposits were demonstrated in tissues by immunohistochemistry, immunofluorescence, and electron microscopy. Some of, but not all, the animals that developed these reactions had detectable antidrug antibodies or circulating immune complexes accompanied by loss of drug exposure and pharmacodynamic effect. On the basis of clinical evidence to date, hypersensitivity reactions following obinutuzumab are rare, further supporting the general view that incidence and manifestation of immunogenicity in nonclinical species are generally not predictive for humans.<\/jats:p>","DOI":"10.1177\/0192623317723539","type":"journal-article","created":{"date-parts":[[2017,8,23]],"date-time":"2017-08-23T03:28:41Z","timestamp":1503458921000},"page":"676-686","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":20,"title":["Hypersensitivity Reactions to Obinutuzumab in Cynomolgus Monkeys and Relevance to Humans"],"prefix":"10.1177","volume":"45","author":[{"given":"Elisabeth","family":"Husar","sequence":"first","affiliation":[{"name":"Pharmaceutical Sciences, Roche Innovation Center Basel, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Solonets","sequence":"additional","affiliation":[{"name":"Safety Science, F. Hoffmann\u2013La Roche, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olaf","family":"Kuhlmann","sequence":"additional","affiliation":[{"name":"Pharmaceutical Sciences, Roche Innovation Center Basel, Basel, Switzerland"},{"name":"Boehringer Ingelheim, Ingelheim, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eginhard","family":"Schick","sequence":"additional","affiliation":[{"name":"Pharmaceutical Sciences, Roche Innovation Center Basel, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanna","family":"Piper-Lepoutre","sequence":"additional","affiliation":[{"name":"Safety Science, F. Hoffmann\u2013La Roche, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Singer","sequence":"additional","affiliation":[{"name":"Pharmaceutical Sciences, Roche Innovation Center Basel, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaurav","family":"Tyagi","sequence":"additional","affiliation":[{"name":"Pharmaceutical Sciences, Roche Innovation Center New York, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2017,8,23]]},"reference":[{"key":"bibr1-0192623317723539","doi-asserted-by":"publisher","DOI":"10.1007\/s11095-011-0523-5"},{"key":"bibr2-0192623317723539","first-page":"10","volume":"6","author":"Bugelski P. J.","year":"2004","journal-title":"Curr Opin Mol Ther"},{"key":"bibr3-0192623317723539","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2017.1290037"},{"key":"bibr4-0192623317723539","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-04-346700"},{"key":"bibr5-0192623317723539","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M510171200"},{"key":"bibr6-0192623317723539","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1313984"},{"key":"bibr7-0192623317723539","doi-asserted-by":"publisher","DOI":"10.1177\/0192623314522559"},{"key":"bibr8-0192623317723539","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-12-395541"},{"key":"bibr9-0192623317723539","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymeth.2005.01.001"},{"key":"bibr10-0192623317723539","unstructured":"ICH Harmonised Tripartite Guideline. (2011). S6(R1) Preclinical safety evaluation of biotechnology-derived pharmaceuticals. Retrieved from International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use, ICH Guidelines website. Accessed April 3, 2017. http:\/\/www.ich.org\/fileadmin\/Public_Web_Site\/ICH_Products\/Guidelines\/Safety\/S6_R1\/Step4\/S6_R1_Guideline.pdf."},{"key":"bibr11-0192623317723539","doi-asserted-by":"publisher","DOI":"10.1177\/0192623313510987"},{"key":"bibr12-0192623317723539","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-06-225979"},{"key":"bibr13-0192623317723539","first-page":"571","volume-title":"Janeway\u2019s Immunobiology","author":"Murphy K.","year":"2011","edition":"8"},{"key":"bibr14-0192623317723539","unstructured":"Pharmacology Review of Drug Approval Package for Natalizumab. (2004). Retrieved from FDA\u2019s Drugs@FDA database. Accessed December 12, 2014. http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2004\/125104s000_Natalizumab.cfm."},{"key":"bibr15-0192623317723539","doi-asserted-by":"publisher","DOI":"10.1016\/j.yrtph.2009.03.012"},{"key":"bibr16-0192623317723539","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.104.079277"},{"key":"bibr17-0192623317723539","doi-asserted-by":"publisher","DOI":"10.1177\/0192623314526475"},{"key":"bibr18-0192623317723539","doi-asserted-by":"publisher","DOI":"10.1177\/0192623313520351"},{"key":"bibr19-0192623317723539","doi-asserted-by":"publisher","DOI":"10.1134\/S0006297909050010"},{"key":"bibr20-0192623317723539","first-page":"63","volume":"16","author":"Solling J.","year":"1981","journal-title":"Clin Nephrol"},{"key":"bibr21-0192623317723539","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpba.2009.12.029"},{"key":"bibr22-0192623317723539","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-05-351411"}],"container-title":["Toxicologic Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/0192623317723539","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/0192623317723539","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/0192623317723539","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T16:38:42Z","timestamp":1777653522000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/0192623317723539"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7]]},"references-count":22,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2017,7]]}},"alternative-id":["10.1177\/0192623317723539"],"URL":"https:\/\/doi.org\/10.1177\/0192623317723539","relation":{},"ISSN":["0192-6233","1533-1601"],"issn-type":[{"value":"0192-6233","type":"print"},{"value":"1533-1601","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,7]]}}}